

Hannah Johannsen, Kathrin Godthardt, Claudia Schreiner, Andrea Völkel, Kristin Noack, Frank Jüngerkes, Carola Barth, Nadine Mockel-Tenbrinck, Silke Schult, Dominik Eckardt, Andreas Bosio, Sebastian Knöbel
Miltenyi Biotec GmbH, Bergisch Gladbach, Germany

Introduction

Human pluripotent stem cells (PSCs) play an important role in disease modeling and drug discovery. Moreover, they hold great promise for future clinical applications, especially due to their potential usage in cell therapy. Therefore, optimal storage and cryopreservation of stem cells and progenies is of major importance. Our new animal component-free, chemically defined media formulation has been specifically designed for use with

xeno- and serum-free culture systems. It ensures not only high recovery and viability but also functionality of different cell types right after thawing. The chemically defined nature of the formulation will allow rapid translation into a clinical-grade medium designed following the recommendations of USP <1043> on ancillary materials.

Results

1 StemMACS™ Cryo-Brew ensures high recovery and viability after cryopreservation of induced pluripotent stem cells (iPSCs)

Human iPSCs frozen in StemMACS™ Cryo-Brew showed a reliable and reproducible recovery of over 93% after thawing (mean \pm SD, $n \geq 3$) as well as a viability of over 88% post-thaw (mean \pm SD, $n \geq 3$) (A). Additionally, fast recovery after replating could be observed, with doubling times of less than 2.12 days (mean \pm SD, $n \geq 4$). iPSCs showed typical stem cell morphology shortly after plating (example shown for cell line A on day 4 after thawing) (A). Marker expression was checked in passage 1 after thawing. The different cell lines

displayed a high expression of pluripotency markers such as TRA-1-60, SSEA-4, SSEA-5, Oct3/4 and Sox2 while showing low expression of the differentiation marker SSEA-1 (example shown for cell line C). A heat map of the analyzed markers was used to visualize the percentage of double- and single-positive cells (B). To determine the genomic stability of iPSCs cryopreserved in our medium, we analyzed the karyotype in passage 5 post-thaw ($n = 2$, example shown for cell line B) (C).




Figure 1

2 Immunosuppressive potential of mesenchymal stem cells (MSCs) is preserved after cryopreservation in StemMACS™ Cryo-Brew

MSCs were isolated from human bone marrow samples and cryopreserved in StemMACS™ Cryo-Brew after expansion (passage 6). The cells showed a recovery of over 89% (mean \pm SD, $n \geq 2$) and a viability of over 92% (mean \pm SD, $n \geq 2$) after thawing as well as a low doubling time of 0.81 days (mean \pm SD, $n = 3$) (A). To assess their immunosuppressive potential, MSCs were

co-cultured with activated T cells. Freshly thawed MSCs were compared to MSCs from the same donor that were maintained in culture (mean \pm SD, $n \geq 2$) (B). Immunosuppressive properties were not negatively affected by the freezing step, thus ensuring full cellular functionality right after thawing.




Figure 2

3 CD34⁺ hematopoietic stem cells (HSCs) show high recovery, viability, and functionality after cryopreservation in StemMACS™ Cryo-Brew

CD34⁺ HSCs, isolated from umbilical cord blood, were frozen in StemMACS™ Cryo-Brew. After thawing, the HSCs showed the expected recovery of 40% (mean \pm SD, $n = 3$) and a high viability of over 95% (mean \pm SD, $n = 3$). Furthermore, the HSCs could be expanded in culture 23.4-fold within seven days after thawing (mean \pm SD, $n = 3$) and showed a CD34⁺

cell frequency of nearly 70% (mean \pm SD, $n = 3$) (A). To assess the differentiation potential of the cells, colony-forming unit (CFU) assays were performed right after thawing. HSC stored in StemMACS Cryo-Brew showed normal CFU formation, including CFU-GEMMs, indicating full preservation of HSC differentiation capacity (mean \pm SD, $n = 3$) (B).




Figure 3

4 StemMACS™ Cryo-Brew enables cryopreservation of iPSC-derived cardiomyocytes with high recovery and viability

Human iPSCs were differentiated into cardiomyocytes and enriched using the PSC-derived Cardiomyocyte Isolation Kit. Cardiomyocytes cryopreserved in StemMACS™ Cryo-Brew showed good recovery of over 95% (mean \pm SD, $n = 2$) and high viability of over

70% after thawing (mean \pm SD, $n = 2$). Furthermore, the enriched cardiomyocytes initiated contractions as early as 24 hours after thawing indicating full functionality, independently of the freezing process.




Figure 4

5 Human chimeric antigen-receptor (CAR T) cells show high recovery and viability after cryopreservation in StemMACS™ Cryo-Brew

Human CD4⁺/CD8⁺ T cells were isolated from leukapheresis, stimulated, and cultivated using the CliniMACS Prodigy®. Cells were further transduced with CD20-CAR via lentiviral transduction to generate gene-modified T cells with the TCT (T Cell

Transduction) Process on the CliniMACS Prodigy. After cryopreservation in StemMACS™ Cryo-Brew the CAR T cells showed high recovery of nearly 85% (mean \pm SD, $n = 2$) and a viability of over 90% (mean \pm SD, $n = 2$).




Figure 5

Conclusion

We have developed an animal-component free and chemically defined freezing medium that ensures high recovery, viability, and functionality after cryopreservation of the following cell types:

- Induced pluripotent stem cells
- Mesenchymal stem cells
- CD34⁺ hematopoietic stem cells
- iPSC-derived cardiomyocytes
- CD4⁺/CD8⁺ CAR T cells

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. The CliniMACS™ System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485. In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for in vitro use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans the national legislation and regulations - e.g. for the EU the Directive 2004/23/EC ("human tissues and cells"), or the Directive 2002/98/EC ("human blood and blood components") - must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System. In the US, the CliniMACS Prodigy™ T Cell Transduction Process is available for research use only. In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved; all other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application or Investigational Device Exemption (IDE). CliniMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use. CliniMACS, CliniMACS Prodigy, StemMACS, MACS, and the MACS logo are registered trademarks or trademarks of Miltenyi Biotec GmbH and/or its affiliates. All other trademarks mentioned in this document are the property of their respective owners and are used for identification purposes only. Copyright © 2016 Miltenyi Biotec GmbH and/or its affiliates. All rights reserved.